Vivien Veninga
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Vivien Veninga has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Emile E. Voest
Oncode Institute, Utrecht, the Netherlands
3 shared publications - Jitske van Den Bulk
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
2 shared publications - John B. A. G. Haanen
The Netherlands Cancer Institute
2 shared publications - Lodewyk F. A. Wessels
The Netherlands Cancer Institute, Amsterdam, The Netherlands
2 shared publications - Myriam Chalabi
Department of Medical Oncology The Netherlands Cancer Institute Amsterdam The Netherlands
2 shared publications - Natasja L. de Vries
Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 11 January 2023
- Published by Springer Nature in Nature
- Vol. 613 (7945) , 743-750
γδ T cells are effectors of immunotherapy in cancers with HLA class I defects
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB)1,2. Here, in contrast to other cancer types3–5, we observed that 20 out of 21 (95%) MMR-d cancers with genomic inactivation of β2-microglobulin (encoded by B2M) retained responsiveness to ICB, suggesting the involvement of immune effector cells other than CD8+ T cells in this context. We next identified a strong association between B2M inactivation and increased infiltration by γδ T cells in MMR-d cancers. These γδ T cells mainly comprised the Vδ1 and Vδ3 subsets, and expressed high levels of PD-1, other activation markers, including cytotoxic molecules, and a broad repertoire of killer-cell immunoglobulin-like receptors. In vitro, PD-1+ γδ T cells that were isolated from MMR-d colon cancers exhibited enhanced reactivity to human leukocyte antigen (HLA)-class-I-negative MMR-d colon cancer cell lines and B2M-knockout patient-derived tumour organoids compared with antigen-presentation-proficient cells. By comparing paired tumour samples from patients with MMR-d colon cancer that were obtained before and after dual PD-1 and CTLA-4 blockade, we found that immune checkpoint blockade substantially increased the frequency of γδ T cells in B2M-deficient cancers. Taken together, these data indicate that γδ T cells contribute to the response to immune checkpoint blockade in patients with HLA-class-I-negative MMR-d colon cancers, and underline the potential of γδ T cells in cancer immunotherapy.
- 11 January 2023
- Published by Springer Nature in Nature
- Vol. 613 (7945) , 743-750
Top Cited PapersOpen Accessγδ T cells are effectors of immunotherapy in cancers with HLA class I defects
DNA mismatch repair-deficient (MMR-d) cancers present an abundance of neoantigens that is thought to explain their exceptional responsiveness to immune checkpoint blockade (ICB)1,2. Here, in contrast to other cancer types3–5, we observed that 20 out of 21 (95%) MMR-d cancers with genomic inactivation of β2-microglobulin (encoded by B2M) retained responsiveness to ICB, suggesting the involvement of immune effector cells other than CD8+ T cells in this context. We next identified a strong association between B2M inactivation and increased infiltration by γδ T cells in MMR-d cancers. These γδ T cells mainly comprised the Vδ1 and Vδ3 subsets, and expressed high levels of PD-1, other activation markers, including cytotoxic molecules, and a broad repertoire of killer-cell immunoglobulin-like receptors. In vitro, PD-1+ γδ T cells that were isolated from MMR-d colon cancers exhibited enhanced reactivity to human leukocyte antigen (HLA)-class-I-negative MMR-d colon cancer cell lines and B2M-knockout patient-derived tumour organoids compared with antigen-presentation-proficient cells. By comparing paired tumour samples from patients with MMR-d colon cancer that were obtained before and after dual PD-1 and CTLA-4 blockade, we found that immune checkpoint blockade substantially increased the frequency of γδ T cells in B2M-deficient cancers. Taken together, these data indicate that γδ T cells contribute to the response to immune checkpoint blockade in patients with HLA-class-I-negative MMR-d colon cancers, and underline the potential of γδ T cells in cancer immunotherapy.
- Open Access
γδ T cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects
DNA mismatch repair deficient (MMR-d) cancers present an abundance of neoantigens that likely underlies their exceptional responsiveness to immune checkpoint blockade (ICB) 1,2 . However, MMR-d colon cancers that evade CD8 + T cells through loss of Human Leukocyte Antigen (HLA) class I-mediated antigen presentation 3–6 , frequently remain responsive to ICB 7 suggesting the involvement of other immune effector cells. Here, we demonstrate that HLA class I-negative MMR-d cancers are highly infiltrated by γδ T cells. These γδ T cells are mainly composed of Vδ1 and Vδ3 subsets, and express high levels of PD-1, activation markers including cytotoxic molecules, and a broad repertoire of killer-cell immunoglobulin-like receptors (KIRs). In vitro , PD-1 + γδ T cells, isolated from MMR-d colon cancers, exhibited a cytolytic response towards HLA class I-negative MMR-d colon cancer cell lines and β 2 - microglobulin ( B2M )-knockout patient-derived tumor organoids (PDTOs), which was enhanced as compared to antigen presentation-proficient cells. This response was diminished after blocking the interaction between NKG2D and its ligands. By comparing paired tumor samples of MMR-d colorectal cancer patients obtained before and after dual PD-1 and CTLA-4 blockade, we found that ICB profoundly increased the intratumoral frequency of γδ T cells in HLA class I-negative cancers. Taken together, these data indicate that γδ T cells contribute to the response to ICB therapy in patients with HLA class I-negative, MMR-d colon cancers, and illustrate the potential of γδ T cells in cancer immunotherapy.
Open Accessγδ T cells are effectors of immune checkpoint blockade in mismatch repair-deficient colon cancers with antigen presentation defects
DNA mismatch repair deficient (MMR-d) cancers present an abundance of neoantigens that likely underlies their exceptional responsiveness to immune checkpoint blockade (ICB) 1,2 . However, MMR-d colon cancers that evade CD8 + T cells through loss of Human Leukocyte Antigen (HLA) class I-mediated antigen presentation 3–6 , frequently remain responsive to ICB 7 suggesting the involvement of other immune effector cells. Here, we demonstrate that HLA class I-negative MMR-d cancers are highly infiltrated by γδ T cells. These γδ T cells are mainly composed of Vδ1 and Vδ3 subsets, and express high levels of PD-1, activation markers including cytotoxic molecules, and a broad repertoire of killer-cell immunoglobulin-like receptors (KIRs). In vitro , PD-1 + γδ T cells, isolated from MMR-d colon cancers, exhibited a cytolytic response towards HLA class I-negative MMR-d colon cancer cell lines and β 2 - microglobulin ( B2M )-knockout patient-derived tumor organoids (PDTOs), which was enhanced as compared to antigen presentation-proficient cells. This response was diminished after blocking the interaction between NKG2D and its ligands. By comparing paired tumor samples of MMR-d colorectal cancer patients obtained before and after dual PD-1 and CTLA-4 blockade, we found that ICB profoundly increased the intratumoral frequency of γδ T cells in HLA class I-negative cancers. Taken together, these data indicate that γδ T cells contribute to the response to ICB therapy in patients with HLA class I-negative, MMR-d colon cancers, and illustrate the potential of γδ T cells in cancer immunotherapy.
- Top Cited Papers
- 1 September 2021
- Published by Elsevier in Cancer Cell
- Vol. 39 (9) , 1190-1201
Tumor organoids: Opportunities and challenges to guide precision medicine
- 1 September 2021
- Published by Elsevier in Cancer Cell
- Vol. 39 (9) , 1190-1201
Top Cited PapersTumor organoids: Opportunities and challenges to guide precision medicine